A Phase 1 interventional study of ABSK061 and ABSK061 in Healthy, sponsored by Abbisko Therapeutics Co, Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To main objective is to evaluate the safety, tolerability, and pharmacokinetic profile of single or multiple oral doses of ABSK061 mini-tablets and to evaluate the effect of soft food with ABSK061 mini-tablets on its pharmacokinetic profile in healthy adult participants
Abbisko Therapeutics Co, Ltd is the lead sponsor of 38 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pharmacokinetic profile (PK) and safety of a single oral dose
Drug: ABSK061
The safety, tolerability, and PK profile of multiple oral doses of ABSK061
Drug: ABSK061
Food Effect Tablet Formulation
Drug: ABSK061
A total of 18 healthy participants were planned to be enrolled in Part I and randomized 1: 1: 1 to Sequences A, B, and C. Participants in three sequences received a single dose of ABSK061 at doses of 1 mg, 10 mg, and 35 mg.
A total of 12 healthy participants were planned to be enrolled in Part II, with multiple dose escalation trials prespecified in Sequences D and E, with 6 healthy participants in each sequence. In this MAD study, participants in Sequence D received ABSK061 microchips 5 mg QD(once a day) for 4 consecutive days.
Part III plans to include 12 healthy participants randomized 1: 1: 1 to Sequence F, Sequence G, or Sequence H to receive a single oral dose of ABSK061 in triplicate doses of Treatment 1, Treatment 2, Treatment 3. Treatment 1 is 5 mg ABSK061 taken with 180 mL of water, Treatment 2 is 5 mg ABSK061 taken with a spoon of yogurt (approximately 15 mL), and Treatment 3 is administered with 5 mg ABSK061 with a spoon of applesauce (approximately 15 mL).
Pharmacokinetics single-dose Cmax
maximum plasma concentration (Cmax)
Time frame: Up to 48 hours post-dose
Pharmacokinetics multiple-dose Cmax
maximum steady-state plasma concentration (Cmax)
Time frame: Up to 24 hours post-dose
Pharmacokinetics multiple-dose Cmin
average steady-state trough plasma concentration (Cmin)
Time frame: Up to 24 hours post-dose
Pharmacokinetics single dose Tmax
time to reach maximum plasma concentration (Tmax)
Time frame: Up to 48 hours post-dose
Pharmacokinetics single and multiple dose AUC
area under the plasma concentration-time curve (AUC)
Time frame: Up to 48 hours post-dose
Pharmacokinetics multiple-dose RAUC
accumulation ratio for AUC
Time frame: Up to 24 hours post-dose
Pharmacokinetics multiple-dose RCmax
accumulation ratio for Cmax (RCmax)
Time frame: Up to 24 hours post-dose
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
number of participants with adverse events (AEs), serious adverse events (SAEs), as a measure of safety and tolerability
Time frame: Initiation of study treatment up to 18-days post treatment
Number of participants with abnormal laboratory tests results and abnormal physical exam findings
Frequency in changes in laboratory parameters and physical signs of toxicity
Time frame: Initiation of study treatment up to 18-days post treatment
Pharmacokinetics single dose CL/F
apparent total clearance (CL/F)
Time frame: Up to 48 hours post-dose
Pharmacokinetics single dose Vz/F
apparent volume of distribution (Vz/F)
Time frame: Up to 48 hours post-dose
Pharmacokinetics single dose t1/2
half-life of ABSK061
Time frame: Up to 48 hours post-dose
Plan to share: Undecided
Ran from May 2025 to primary completion in Jul 2025, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABSK061
Abbisko Therapeutics Co, Ltd →